Model examination of chemoprevention with retinoids in squamous cell carcinomas of the head and neck region and suitable biomarkers for chemoprevention

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1083-1097

  Fabricius, Eva Maria ^a   Kruse Boitschenko, Ute ^a   Schneeweiss, Ulrich ^b   Wildner, Gustav Paul ^b   Hoffmeister, Bodo ^a   Raguse, Jan Dirk ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Section of Pathology   (Germany)

Author keywords

APAAP; ATRA; Biomarker; Chemoprevention; Cytospins; Frozen sections; HaCaT; Head and neck squamous cell carcinoma; Immunocytochemistry; Immunohistochemistry; Ki 67; MTT; p53; RAR; RXR; Telomerase; UM SCC 14C; UM SCC 35; XTT

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; KI 67 ANTIGEN; PROTEIN P53; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; RETINOID X RECEPTOR GAMMA; TELOMERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; RECEPTORS, RETINOIC ACID; RETINOIDS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 80053204421     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1139     Document Type: Article

References (152)

1. Slaughter D, Southwick H and Smejkal W: 'Field cancerization' in oral stratified squamous epithelium. Cancer 6: 963-968, 1953.
2. Van Oijen M and Slootweg P: Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol Biomarkers Prev 9: 249-256, 2000. (Pubitemid 30165436)
3. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR and Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727-1730, 2003. (Pubitemid 36460827)
4. Ha PK and Califano JA: The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 14: 363-369, 2003. (Pubitemid 44560790)
5. Gath H and Brakenhoff RH: Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 18: 109-126, 1999. (Pubitemid 29411096)
6. Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, Tesfa-Selase F and Langdon JD: Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res 6: 2718-2725, 2000. (Pubitemid 30482110)
7. Van Houten VM, Tabor MP, Van den Brekel MW, Denkers F, Wishaupt RG, Kummer JA, Snow GB and Brakenhoff RH: Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 6: 3803-3816, 2000.
8. Graveland AP, de Maaker M, Braakhuis BJ, de Bree R, Eerenstein SE, Bloemena E, Leemans CR and Brakenhoff RH: Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients. Cell Oncol 31: 317-328, 2009.
9. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW and Goepfert H: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801, 1990. (Pubitemid 20303877)
10. Benner SE, Lippman SM and Hong WK: Prevention of second head and neck cancer. Semin Radiat Oncol 2: 206-212, 1992.
11. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y and Laplanche A: Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30: 767-772, 1994. (Pubitemid 24217331)
12. Fountzilas G: Retinoids in the management of head and neck cancer. An update. J Chemother 6: 127-138, 1994.
13. Huber MH and Hong WK: Biology and chemoprevention of head and neck cancer. Curr Probl Cancer 18: 86-140, 1994.
14. Lippman SM, Heyman RA, Kurie JM, Benner SE and Hong WK: Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem 22: 1-10, 1995.
15. Lippman SM, Spitz MR, Huber MH and Hong WK: Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck. Curr Opin Oncol 7: 234-241, 1995.
16. Lotan R: Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev 16: 349-356, 1997.
17. Geyer C, Papadimitrakopoulou V and Hong WK: Chemoprevention in head and neck cancer: basic science and clinical application. Semin Radiat Oncol 8: 292-301, 1998. (Pubitemid 28460814)
18. Lee J, Hong W, Hittelman W, Mao L, Lotan R, Shin D, Benner S, Xu X, Lee J, Papadimitrakopoulou V, Geyer C, Perez C, Martin J, El-Naggar A and Lippman S: Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6: 1702-1710, 2000. (Pubitemid 30305062)
19. Papadimitrakopoulou VA: Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. Curr Opin Oncol 12: 240-245, 2000.
20. Braakhuis BJ, Brakenhoff RH and Leemans CR: Second field tumors: a new opportunity for cancer prevention? Oncologist 10: 493-500, 2005. (Pubitemid 41266330)
21. Sudbø J and Reith A: The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer 115: 339-345, 2005. (Pubitemid 40663735)
22. Braakhuis BJ, Leemans CR and Brakenhoff RH: Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol 15: 113-120, 2005. (Pubitemid 40126242)
23. Braakhuis BJ, Bloemena E, Leemans CR and Brakenhoff RH: Molecular analysis of surgical margins in head and neck cancer: More than a marginal issue. Oral Oncol 46: 485-491, 2010.
24. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36: 2699-2702, 1976.
25. Sporn MB, Dunlop NM, Newton DL and Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332-1338, 1976.
26. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN): Nomenclature of retinoids - recommendations 1981. Eur J Biochem 129: 1-5, 1982.
27. Hong WK, Spitz MR and Lippman SM: Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol 18: S9-S18, 2000.
28. Klaassen I and Braakhuis BJ: Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol 38: 532-542, 2002. (Pubitemid 34880115)
29. Tsao AS, Kim ES and Hong WK: Chemoprevention of cancer. CA Cancer J Clin 54: 150-180, 2004. (Pubitemid 38812180)
30. Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, Giordano C, Benazzo M, Caroggio A, Cavalot AL, Gandolfo S, Garozzo A, Margarino G, Schenone G, Spadini N, Sirotovà Z, Zibordi F, Balzarini F, Serafini I, Miani P and Cortesina G: 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 11: 1297-1305, 2004.
31. Perry CF, Stevens M, Rabie I, Yarker ME, Cochrane J, Perry E, Traficante R and Coman W: Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 131: 198-203, 2005. (Pubitemid 40349917)
32. Lotan R: Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res 16: 2415-2419, 1996.
33. Ran L, Tan W, Tan S, Zhang R, Wang W and Zeng W: Effects of ATRA, acitretin and tazarotene on growth and apoptosis of Tca8113 cells. J Huazhong Univ Sci Technolog Med Sci 25: 393-396, 2005.
34. Zhang X, Chen ZG, Khuri FR and Shin DM: Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. Head Neck 29: 351-361, 2007. (Pubitemid 46623500)
35. Giannini F, Maestro R, Vukosavljevic T, Pomponi F and Boiocchi M: All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J Cancer 70: 194-200, 1997. (Pubitemid 27107417)
36. Hayashi K, Yokozaki H, Naka K, Yasui W, Yajin K, Lotan R and Tahara E: Effect of 9-cis-retinoic acid on oral squamous cell carcinoma cell lines. Cancer Lett 151: 199-208, 2000. (Pubitemid 30156795)
37. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S and Weinstein I: The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 93: 329-339, 2002. (Pubitemid 34464370)
38. Xiao B, Guo J, Lou Y, Meng D, Zhao W, Zhang L, Yan C and Wang D: Inhibition of growth and increase of alkaline phosphatase activity in cultured human oral cancer cells by all-trans retinoic acid. Int J Oral Maxillofac Surg 35: 643-648, 2006. (Pubitemid 43863125)
39. Wang A, Zeng R and Huang H: Retinoic acid and sodium butyrate as cell cycle regulators in the treatment of oral squamous carcinoma cells. Oncol Res 17: 175-182, 2008.
40. Klass CM and Shin DM: Current status and future perspectives of chemoprevention in head and neck cancer. Curr Cancer Drug Targets 7: 623-632, 2007.
41. Wrangle JM and Khuri FR: Chemoprevention of squamous cell carcinoma of the head and neck. Curr Opin Oncol 19: 180-187, 2007. (Pubitemid 46597475)
42. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H and Hong WK: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328: 15-20, 1993. (Pubitemid 23011466)
43. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fux K, Shin DM, Vokes EE, Feng L, Goepfert H and Hong WK: Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98: 441-450, 2006.
44. Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK and Lippman SM: Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27: 599-604, 2009.
45. Lippman SM, Benner SE and Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851-873, 1994. (Pubitemid 24110928)
46. Scully C: Oral precancer: preventive and medical approaches to management. Eur J Cancer B Oral Oncol 31: 16-26, 1995.
47. Freemantle SJ, Dragnev KH and Dmitrovsky E: The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 98: 426-427, 2006.
48. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM and Mao L: ΔNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res 15: 6284-6291, 2009.
49. Tradati N, Grigolat IR, Calabrese L, Costa L, Giugliano G, Morelli F, Scully C, Boyle P and Chiesa F: Oral leukoplakias: to treat or not? Oral Oncol 33: 317-321, 1997. (Pubitemid 28138073)
50. Sun SY and Lotan R: Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41: 41-55, 2002.
51. van Zandwijk N, Dalesio O, Pastorino U, de Vries N and van Tinteren H: EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977-986, 2000.
52. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H and Hong WK: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarker Prev 10: 823-829, 2001. (Pubitemid 32738594)
53. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK and Spitz MR: Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 14: 131-138, 2003. (Pubitemid 36539519)
54. Eicher SA and Lotan R: Differential effects of retinoic acid and N-(4-hydroxyphenyl) retinamide on head and neck squamous cell carcinoma cells. Laryngoscope 106: 1471-1475, 1996. (Pubitemid 26415252)
55. Braakhuis B, Klaassen I, Van der Leede B, Cloos J, Brakenhoff R, Copper M, Teerlink T, Hendriks H, Van der Saag P and Snow G: Retinoid metabolism and all-trans retinoid acid-induced growth inhibition in head and neck squamous cell carinoma cell lines. Br J Cancer 76: 189-197, 1997. (Pubitemid 27279658)
56. Zou CP, Youssef EM, Zou CC, Carey TE and Lotan R: Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. Oncogene 20: 6820-6827, 2001. (Pubitemid 33052172)
57. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G and Veronesi U: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54: S2032-S2237, 1994.
58. Chandraratna RA: Tazarotene-first of a new generation of receptor-selective retinoids. Br J Dermatol 135: 18-25, 1996.
59. Dimery IW, Hong WK, Lee JJ, Guillory-Perez C, Pham F, Fritsche HA Jr and Lippman SM: Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8: 85-89, 1997. (Pubitemid 27112807)
60. Schwartz JL: Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med 11: 92-122, 2000.
61. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RA, Shudo K, Hong WK and Lotan R: Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 6: 1563-1573, 2000. (Pubitemid 30226247)
62. Kelloff GJ: Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 78: 199-334, 2000.
63. Klaholz BP, Mitschler A and Moras D: Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J Mol Biol 302: 155-170, 2000.
64. Chun KH, Pfahl M and Lotan R: Induction of apoptosis by the synthetic retinoid MX3350-1 through extrinsic and intrinsic pathways in head and neck squamous carcinoma cells. Oncogene 24: 3669-3677, 2005. (Pubitemid 40756236)
65. Brelsford M and Beute TC: Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 27: 197-206, 2008.
66. Petkovich M, Brand NJ, Krust A and Chambon P: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330: 444-450, 1987. (Pubitemid 18006425)
67. Giguere V, Ong ES, Segui P and Evans RM: Identification of a receptor for the morphogen retinoic acid. Nature 330: 624-629, 1987. (Pubitemid 18005577)
68. Mangelsdorf DJ, Ong ES, Dyck JA and Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345: 224-228, 1990.
69. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM and Thaller C: 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68: 397-406, 1992.
70. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A and Evans RM: Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 6: 329-344, 1992.
71. Dawson MI: Synthetic retinoids and their nuclear receptors. Curr Med Chem Anticancer Agents 4: 199-230, 2004.
72. Schweitzer A, Knauer SK and Stauber RH: Nuclear receptors in head and neck cancer: current knowledge and perspectives. Int J Cancer 126: 801-809, 2010.
73. Stauber RH, Wünsch D, Knauer SK and Fetz V: An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck. Histol Histopathol 25: 1093-1104, 2010.
74. Brand N, Petkovich M, Krust A, Chambon P, de Thé H, Marchio A, Tiollais P and Dejean A: Identification of a second human retinoic acid receptor. Nature 332: 850-853, 1988.
75. Mangelsdorf DJ, Ong ES, Dyck JA and Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345: 224-229, 1990.
76. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954, 1996.
77. Fisher GJ, Talwar HS, Xiao JH, Datta SC, Reddy AP, Gaub MP, Rochette-Egly C, Chambon P and Voorhees JJ: Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 269: 20629-20635, 1994. (Pubitemid 24260474)
78. Gann AA, Gates PB, Stark D and Brockes JP: Receptor isoform specificity in a cellular response to retinoic acid. Proc Biol Sci 263: 729-734, 1996. (Pubitemid 26232305)
79. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ and Gronemeyer H: International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 58: 712-725, 2006. (Pubitemid 44833741)
80. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ and Gronemeyer H: International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58: 760-772, 2006. (Pubitemid 44833744)
81. Brown KS and Kane MA: Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngol Clin North Am 39: 349-363, 2006.
82. Desvergne B: RXR: from partnership to leadership in metabolic regulations. Vitam Horm 75: 1-32, 2007.
83. Barnard JH, Collings JC, Whiting A, Przyborski SA and Marder TB: Synthetic retinoids: structure-activity relationships. Chemistry 15: 11430-11442, 2009.
84. Lotan R: Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res 54: S1987-S1990, 1994.
85. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK and Lotan R: Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54: 3580-3587, 1994. (Pubitemid 24225987)
86. Xu XC, Zile MH, Lippman SM, Lee JS, Lee JJ, Hong WK and Lotan R: Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 55: 5507-5511, 1995.
87. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, Hittelman WN and Hong WK: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55: 16-19, 1995.
88. Lotan R, Xu X-C, Lippman SM, Ro JY, Lee JS, Lee JJ and Hong W: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332: 1405-1410, 1995.
89. Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, Batsakis JG, Ro JY, Martin JW, Hittelman WN, Lotan R and Hong WK: Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 3: 875-880, 1997. (Pubitemid 27252935)
90. Papadimitrakopoulou VA and Hong WK: Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer 88: 852-855, 2000.
91. Karamouzis MV, Sotiropoulou-Bonikou G, Vandoros G, Varakis I and Papavassiliou AG: Retinoid-X-receptor alpha (RXRalpha) expression during laryngeal carcinogenesis: detrimental or beneficial event? Cancer Lett 199: 175-183, 2003. (Pubitemid 37297710)
92. Ralhan R, Chakravarti N, Kaur J, Sharma C, Kumar A, Mathur M, Bahadur S, Shukla NK and Deo SV: Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int J Cancer 118: 1077-1089, 2006. (Pubitemid 43185593)
93. Olasz J, Juhász A, Remenár E, Engi H, Bak M, Csuka O and Kásler M: RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age. Oncol Rep 18: 105-112, 2007.
94. Khuri F, Lippman S, Spitz M, Lotan R and Hong W: Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 89: 199-211, 1997. (Pubitemid 27073757)
95. Lippman SM, Sudbø J and Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23: 346-356, 2005. (Pubitemid 46206883)
96. Boyle P, Chiesa F and Scully C: Chemoprevention and oral cancer-(more) trials and (more) tribulations. Eur J Cancer B Oral Oncol 31: 1-2, 1995.
97. Zänker KS: Chemoprevention of cancer for the next millennium-quo vadis? Cancer Lett 143: S7-S11, 1999.
98. Copper MP, Braakhuis BJM, De Vries N, Van Dongen GA, Nauta JJP and Snow GB: A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoint in chemoprevention trials. Cancer 71: 825-830, 1993. (Pubitemid 23051388)
99. Kim J and Shin DM: Biomarkers of squamous cell carcinoma of the head and neck. Histol Histopathol 12: 205-218, 1997. (Pubitemid 27106932)
100. Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC and Kelloff GJ: Development of new cancer chemoprevention agents: role of pharmacokinetic/ pharmacodynamic and intermediate endpoint biomarker monitoring. Clinical Chemistry 44: 420-427, 1998. (Pubitemid 28087750)
101. Koch W: Clinical implications of biomarkers in head and neck cancer. Curr Oncol Rep 1: 129-137, 1999.
102. Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET and Doody LA: Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9: 127-137, 2000. (Pubitemid 30111934)
103. Kim ES, Hong WK and Khuri FR: Chemoprevention of aerodigestive tract cancers. Annu Rev Med 53: 223-243, 2002. (Pubitemid 34177880)
104. Papadimitrakopoulou V: Chemoprevention of head and neck cancer: an update. Curr Opin Oncol 14: 318-322, 2002.
105. Wirth LJ, Haddad RI and Posner MR: Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther 3: 339-355, 2003. (Pubitemid 36748045)
106. Glover KY and Papadimitrakopoulou VA: Chemoprevention of head and neck cancer. Curr Oncol Rep 5: 152-157, 2003. (Pubitemid 38898778)
107. Smith W and Saba N: Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 55: 143-152, 2005. (Pubitemid 40981916)
108. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG and Hong WK: AACR Task Force on Cancer Prevention: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 12: 3661-3697, 2006. (Pubitemid 44000248)
109. Lippman SM and Hawk ET: Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 69: 5269-5284, 2009.
110. Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axéll T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB, Holmstrup P, Jontell M, Nair R, Sasser H, Schifter M, Silverman B, Thongprasom K, Thornhill M, Warnakulasuriya S and Van der Waal I: Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: S19.e1-S19.e12, 2007.
111. Niles RM: Biomarker and animal models for assessment of retinoid efficacy in cancer chemoprevention. Acta Pharmacologica Sinica 28: 1383-1391, 2007.
112. Mao L, El-Naggar A, Fan Y-H, Lee J, Lippman S, Kayser S, Lotan R and Hong W: Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 56: 5600-5604, 1996. (Pubitemid 26422159)
113. Curran A, Denis K, Irish J, Gullane P, MacMillan C and Kamel-Reod S: Telomerase activity in oral squamous cell carcinoma. Arch Otolaryngol Head and Neck Surgery 124: 784-788, 1998. (Pubitemid 28328813)
114. Patel M, Patel D, Parekh L, Raval G, Rawal R, Bhatavdekar J, Patel B and Patel P: Evaluation of telomerase activation in head and neck cancer. Oral Oncol 35: 510-515, 1999. (Pubitemid 29386788)
115. Sumida T, Hamakawa H, Sogawa K, Sugita A, Tanioka H and Ueda N: Telomerase components as a diagnostic tool in human oral lesions. Int J Cancer 80: 1-4, 1999. (Pubitemid 28559766)
116. Dhaene K, Van Marck E and Parwaresch R: Telomeres, telomerase and cancer: an up-date. Virchows Arch 437: 1-16, 2000. (Pubitemid 30446910)
117. Fabricius E-M, Gurr U and Wildner G-P: Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head and neck. Anal Cell Pathol 24: 25-39, 2002. (Pubitemid 34985077)
118. Fabricius E-M, Kruse-Boitschenko U, Khoury R, Wildner GP, Raguse JD and Klein M: Immunohistocehmical determination of the appropiate anti-hTERT antibodies for in situ detection of telomerase activity in frozen sections of head and neck squamous cell carcinomas and tumor margin tissues. Int J Oncol 34: 1257-1279, 2009.
119. Grénman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, Wolf GT, Lacivita LP, Ho L, Baker SR, Krause CJ and Lichter AS: In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 67: 2741-2747, 1991.
120. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR and Carey TE: Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32: 417-426, 2010.
121. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Makrham A and Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid keratinocyte cell line. J Cell Biol 106: 761-771, 1988. (Pubitemid 18089976)
122. Welters M, Fichtinger-Schepman A, Baan R, Hermsen M, Van der Vijgh W, Cloos J and Braakhuis B: Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 71: 410-415, 1997. (Pubitemid 27224306)
123. Copper M, Klaassen I, Brakenhoff R, Cloos J, Snow G and Braakhuis B: All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines. Oral Oncol 33: 270-274, 1997.
124. Klaassen I, Brakenhoff R, Smeets S, Snow G and Braakhuis B: Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. Int J Cancer 92: 661-665, 2001. (Pubitemid 32385706)
125. Klaassen I, Brakenhoff R, Smeets SJ, Snow G and Braakhuis B: Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br J Cancer 85: 630-635, 2001. (Pubitemid 32808291)
126. Klaassen I, Brakenhoff R, Smeets S, Snow G and Braakhuis B: Enhanced turnover of all-trans-retinoic acid and increased formation of polar metabolites in head and neck squamous cell carcinoma lines compared with normal oral keratinocytes. Clin Cancer Res 7: 1017-1025, 2001. (Pubitemid 32708741)
127. Chen WC, Sass JO, Seltmann H, Nau H, Orfanos CE and Zouboulis CC: Biological effects and metabolism of 9-cis-retinoic acid and its metabolite 9,13-di-cis-retinoic acid in HaCaT keratinocytes in vitro: comparison with all-trans-retinoic acid. Arch Dermatol Res 292: 612-620, 2000. (Pubitemid 32112969)
128. Schroeder M and Zouboulis CC: All-trans-retinoic acid and 13-cis-retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes. Horm Metab Res 39: 136-149, 2007.
129. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein G and Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229, 1984. (Pubitemid 14184314)
130. Remmele W, Hildebrand U, Hienz HA, Klein P-J, Vierbuchen M, Behnken LJ, Heicke B and Scheidt E: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch (Pathol Anat) 409: 127-147, 1986. (Pubitemid 16084979)
131. Wittekind Ch, Meyer HJ und Bootz F (eds): TNM Klassifikation maligner Tumoren. UICC International Union Against Cancer. 6. Aufl. Korr. Nachdruck. Kopf- und Halstumoren (in German) 19-52, 2005.
132. Lowry OH, Rosenbrough NJ, Farr L and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
133. Sachs L: Angewandte Statistik-Anwendung statistischer Methoden. 11. Auflage Springer Verlag, Heidelberg (in German) pp889, 2004.
134. Le Q, Dawson MI, Soprano DR and Soprano KJ: Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene 19: 1457-1465, 2000. (Pubitemid 30171177)
135. Jetten AM, Kim JS, Sacks PG, Rearick JI, Lotan D, Hong WK and Lotan R: Inhibition of growth and squamous-cell differentiation markers in cultured human head and neck squamous carcinoma cells by beta-all-trans retinoic acid. Int J Cancer 45: 195-202, 1990. (Pubitemid 20032121)
136. Lotan R, Sacks PG, Lotan D and Hong WK: Differential effects of retinoic acid on the in vitro growth and cell-surface glycoconjugates of 2 human head and neck squamous-cell carcinomas. Int J Cancer 40: 224-229, 1987. (Pubitemid 17130835)
137. Zou CP, Clifford JL, Xu XC, Sacks PG, Chambon P, Hong WK and Lotan R: Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res 54: 5479-5487, 1994. (Pubitemid 24336044)
138. Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin S, Gonzalez FJ, Ross AC and Peters JM: Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol 74: 1429-1442, 2008.
139. Jang HS, Oh CK, Jo JH, Kim YS and Kwon KS: Detection of telomerase activity in psoriasis lesional skin and correlation with Ki-67 expression and suppression by retinoid acid. J Korean Med Sci 16: 623-629, 2001.
140. Wanner R, Wolff B, Glowacki F, Kolde G and Wittig B: The loss of desmosomes after retinoic acid treatment results in an apparent inhibition of HaCaT keratinocyte differentiation. Arch Dermatol Res 291: 346-353, 1999. (Pubitemid 29281324)
141. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984. (Pubitemid 14035254)
142. D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, Casto B, Milo GE, Kelloff GJ and Steele VE: Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res 21: 3229-3235, 2001. (Pubitemid 34224222)
143. Hauser U, Balz V, Carey T, Grenman R, Van Lierop A, Scheckenbach K and Bier H: Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24: 868-873, 2002. (Pubitemid 34913258)
144. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG and Carey TE: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25: 654-661, 2003. (Pubitemid 36909750)
145. Nakashima T, Sun S, Lotan R, Fujiwara T, Yasumatsu R, Komiyama S and Clayman G: All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Laryngoscope 111: 1459-1464, 2001. (Pubitemid 32730195)
146. Boudjelal M, Voorhees JJ and Fisher GJ: Retinoid signaling is attenuated by proteasome-mediated degradation of retinoid receptors in human keratinocyte HaCaT cells. Exp Cell Res 274: 130-137, 2002.
147. Soo Lee Y, Jin DQ, Beak SM, Lee ES and Kim JA: Inhibition of ultraviolet-A-modulated signaling pathways by asiatic acid and ursolic acid in HaCaT human keratinocytes. Eur J Pharmacol 476: 173-178, 2003. (Pubitemid 37272144)
148. Oridate N, Esumi N, Lotan D, Hing WK, Rochette-Egly C, Chambon P and Lotan R: Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells. Oncogene 12: 2019-2028, 1996. (Pubitemid 26154674)
149. Sherman JA and Partridge M: Expression of retinoic acid receptors in normal, dysplastic and malignant oral epithelia. Br J Oral Maxillofac Surg 35: 260-266, 1997. (Pubitemid 27380058)
150. Wan H, Oridate N, Lotan D, Hong WK and Lotan R: Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res 59: 3518-3526, 1999. (Pubitemid 29334517)
151. Zhang P, Xu Q, Chen WT, Duan LQ, Zhang ZY and Zhou XJ: Synergistic down-regulation of telomerase by all-trans retinoic acid and antisense oligonucleotide in oral squamous cell carcinoma cell line (Tca8113). Oral Oncol 41: 909-1015, 2005.
152. You Y, Lee G and Min B: Retinoic acid extends the in vitro life span of normal human oral keratinocytes by decreasing p16 (INK4A) expression and maintaining telomerase activity. Biochem Biophys Res Commun 268: 268-274, 2000. (Pubitemid 30119610)